Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 25, 2026 13:00 ET | Source: CROSSJECT

CROSSJECT appoints Lionel Seltz as Chief Financial Officer

DIJON, France – 25 mars 2026 (06.00 PM CET) – CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ), the specialty pharmaceuticals company developing emergency medicines based on its proprietary ZENEO®...
March 25, 2026 13:00 ET | Source: CROSSJECT

CROSSJECT nomme Lionel SELTZ au poste de Directeur Administratif et Financier

DIJON, France – 25 mars 2026 (18H00 CET) – CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ), société pharmaceutique de spécialités qui développe des produits dédiés aux situations d’urgence fondés...
March 25, 2026 02:20 ET | Source: CROSSJECT

CROSSJECT publishes its 2025 financial results and confirms the strengthening of its operational, industrial and financial trajectory

DIJON, France – 25 March 2026 (07:20 AM CET) – CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceutical company developing products for emergency situations based on its proprietary...
March 24, 2026 13:30 ET | Source: CROSSJECT

CROSSJECT publie ses résultats financiers 2025 et confirme le renforcement de sa trajectoire opérationnelle, industrielle et financière

DIJON, France – 24 mars 2026 (18H30 CET) – CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ), société pharmaceutique de spécialités qui développe des produits dédiés aux situations d’urgence fondés...